StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

Cartesian Therapeutics cash

Cash and short-term investments held at the end of each period.

Cartesian Therapeutics's cash was $147.61M at Jun 30, 2026. For fiscal 2025 it was $125.14M, down 41.6% from the year before. Over ten years it grew 13.0% a year on average. The highest annual figure on record is $214.28M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$125.14M-41.6%
FY2024Dec 31, 2024$214.28M+173.7%
FY2023Dec 31, 2023$78.29M-42.5%
FY2022Dec 31, 2022$136.20M+6.4%
FY2021Dec 31, 2021$128.06M-8.6%
FY2020Dec 31, 2020$140.06M+53.0%
FY2019Dec 31, 2019$91.55M+143.0%
FY2018Dec 31, 2018$37.68M-61.1%
FY2017Dec 31, 2017$96.97M+14.7%
FY2016Dec 31, 2016$84.54M+129.0%
FY2015Dec 31, 2015$36.91M+122.5%
FY2014Dec 31, 2014$16.59M+105.9%
FY2013Dec 31, 2013$8.06M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$147.61M-7.9%
Q1 FY2026Mar 31, 2026$118.64M-34.2%
Q4 FY2025Dec 31, 2025$125.14M-41.6%
Q3 FY2025Sep 30, 2025$143.38M-34.6%
Q2 FY2025Jun 30, 2025$160.32M+83.8%
Q1 FY2025Mar 31, 2025$180.43M+74.5%
Q4 FY2024Dec 31, 2024$214.28M+173.7%
Q3 FY2024Sep 30, 2024$219.20M+175.4%
Q2 FY2024Jun 30, 2024$87.23M-22.1%
Q1 FY2024Mar 31, 2024$103.42M-17.9%
Q4 FY2023Dec 31, 2023$78.29M-42.5%
Q3 FY2023Sep 30, 2023$79.60M-45.6%
Q2 FY2023Jun 30, 2023$112.03M-21.1%
Q1 FY2023Mar 31, 2023$125.93M+7.2%
Q4 FY2022Dec 31, 2022$136.20M+6.4%
Q3 FY2022Sep 30, 2022$146.44M+5.6%
Q2 FY2022Jun 30, 2022$142.06M-5.4%
Q1 FY2022Mar 31, 2022$117.43M-20.6%
Q4 FY2021Dec 31, 2021$128.06M-8.6%
Q3 FY2021Sep 30, 2021$138.66M-5.2%
Q2 FY2021Jun 30, 2021$150.14M+151.4%
Q1 FY2021Mar 31, 2021$147.81M+103.6%
Q4 FY2020Dec 31, 2020$140.06M+53.0%
Q3 FY2020Sep 30, 2020$146.26M+327.2%
Q2 FY2020Jun 30, 2020$59.73M+43.3%
Q1 FY2020Mar 31, 2020$72.61M+50.0%
Q4 FY2019Dec 31, 2019$91.55M+143.0%
Q3 FY2019Sep 30, 2019$34.23M-32.2%
Q2 FY2019Jun 30, 2019$41.68M-37.1%
Q1 FY2019Mar 31, 2019$48.42M-41.7%
Q4 FY2018Dec 31, 2018$37.68M-61.1%
Q3 FY2018Sep 30, 2018$50.49M-51.6%
Q2 FY2018Jun 30, 2018$66.23M-41.2%
Q1 FY2018Mar 31, 2018$83.07M+21.2%
Q4 FY2017Dec 31, 2017$96.97M+14.7%
Q3 FY2017Sep 30, 2017$104.39M+31.7%
Q2 FY2017Jun 30, 2017$112.66M–
Q1 FY2017Mar 31, 2017$68.52M–
Q4 FY2016Dec 31, 2016$84.54M–
Q3 FY2016Sep 30, 2016$79.28M–

More Cartesian Therapeutics figures

See a number that looks wrong?